Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer

Dynamic contrast-enhanced MRI enables noninvasive analysis of prostate vascularization as well as tumour angiogenesis and capillary permeability characteristics in prostate cancers. Pharmacokinetic models summarizing the complex information provided by signal intensity-time curves for a few quantitative pharmacokinetic parameters are increasingly being used in the routine clinical setting. This review consists of two parts. The first part discusses the advantages and disadvantages of the MR pulse sequences that can be used for performing DCE-MRI and also of the most widely used pharmacokinetic parameters and models and the parameters they describe. The second part outlines the range of current and potential future clinical applications of DCE-MRI and pharmacokinetic parametric maps in patients with prostate cancer, with reference to the current scientific literature on the topic. The potential clinical applications of DCE-MRI for prostate cancer include detection, localization, and staging, differentiation of recurrent cancer and estimation of the patient’s prognosis, as well as monitoring of treatment response.

[1]  M. Roach.  Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". , 2003, International journal of radiation oncology, biology, physics.

[2]  A. Evans,et al.  Clinical predictors of gleason score upgrading , 2007, Cancer.

[3]  G. Brix,et al.  Methods for quantitative assessment of tissue microcirculation using dynamic contrast-enhanced MR imaging , 1997, Der Radiologe.

[4]  E. Rostrup,et al.  Measurement of the arterial concentration of Gd‐DTPA using MRI: A step toward quantitative perfusion imaging , 1996, Magnetic resonance in medicine.

[5]  A Heerschap,et al.  Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors , 2001, Journal of magnetic resonance imaging : JMRI.

[6]  Stacey A. Kenfield,et al.  Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Chinyere N. Onyebuchi,et al.  The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy , 2004, Cancer.

[8]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[9]  A. Moore.  Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment , 1967 .

[10]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[11]  A. Partin,et al.  Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. , 2001, Reviews in urology.

[12]  H. Huisman,et al.  Accurate estimation of pharmacokinetic contrast‐enhanced dynamic MRI parameters of the prostate , 2001, Journal of magnetic resonance imaging : JMRI.

[13]  D. Beyersdorff,et al.  MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  P. Carroll,et al.  Validity of prostate‐specific antigen as a tumour marker in men with prostate cancer managed by watchful‐waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging , 2007, BJU international.

[15]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[16]  Bernd Hamm,et al.  Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. , 2002, Radiology.

[17]  H. Schlemmer,et al.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.

[18]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[19]  Matthias Taupitz,et al.  Evaluation of Normal Prostate Tissue, Chronic Prostatitis, and Prostate Cancer by Quantitative Perfusion Analysis Using a Dynamic Contrast-Enhanced Inversion-Prepared Dual-Contrast Gradient Echo Sequence , 2008, Investigative radiology.

[20]  Masoom A Haider,et al.  Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[21]  D. Dearnaley,et al.  Dynamic contrast-enhanced MRI for prostate cancer localization. , 2009, The British journal of radiology.

[22]  S. Katz,et al.  The Importance of Correct Norms in Blood Volume Measurement , 2007, The American journal of the medical sciences.

[23]  D. Beyersdorff,et al.  [Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer]. , 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[24]  G Brix,et al.  Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.

[25]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[26]  M. Zelefsky.  Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer , 2005 .

[27]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[28]  D. Beyersdorff,et al.  Simultaneous Quantification of Perfusion and Permeability in the Prostate Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with an Inversion-Prepared Dual-Contrast Sequence , 2009, Annals of Biomedical Engineering.

[29]  Janet E. Husband,et al.  The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma , 1995 .

[30]  M. Brawer,et al.  Topography of neovascularity in human prostate carcinoma , 1995, Cancer.

[31]  H. Schlemmer,et al.  Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004 .

[32]  E. Heath,et al.  Angiogenesis inhibitors in the treatment of prostate cancer , 2010, Journal of hematology & oncology.

[33]  S. Kozerke,et al.  Accelerated parallel imaging by transform coding data compression with k-t SENSE , 2006, 2006 International Conference of the IEEE Engineering in Medicine and Biology Society.

[34]  Ting-Yim Lee,et al.  An Adiabatic Approximation to the Tissue Homogeneity Model for Water Exchange in the Brain: II. Experimental Validation , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  Namkug Kim,et al.  Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[36]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[37]  P. Carroll,et al.  Imaging for recurrent prostate cancer. , 2000, Radiologic clinics of North America.

[38]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[39]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[40]  Thomas Hambrock,et al.  Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer After External Beam Radiation Therapy , 2010, Investigative radiology.

[41]  Matthias Taupitz,et al.  Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. , 2009, Radiology.

[42]  I. Floriani,et al.  Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. , 2008, AJR. American journal of roentgenology.

[43]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[44]  J F Gross,et al.  Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. , 1989, International journal of radiation oncology, biology, physics.

[45]  Donald E Bailey,et al.  Active surveillance for early‐stage prostate cancer , 2008, Cancer.

[46]  G. Wright,et al.  Rapid high‐resolution T1 mapping by variable flip angles: Accurate and precise measurements in the presence of radiofrequency field inhomogeneity , 2006, Magnetic resonance in medicine.

[47]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[48]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[49]  B. Vojnovic,et al.  Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI , 2002, NMR in biomedicine.

[50]  M. Knopp,et al.  Dynamic contrast‐enhanced MRI using Gd‐DTPA: Interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors , 2001, Magnetic resonance in medicine.

[51]  D P Dearnaley,et al.  Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. , 2001, Radiology.

[52]  L Axel,et al.  Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. , 1989, Radiology.

[53]  Robert C. Frazier,et al.  Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy , 1999, Cancer.

[54]  A. Neugut,et al.  Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. , 1999, Urology.

[55]  Olivier Rouvière,et al.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy , 2009, European Radiology.

[56]  M. Knopp,et al.  [Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography]. , 1997, Der Radiologe.

[57]  P S Tofts,et al.  Quantitative Analysis of Dynamic Gd‐DTPA Enhancement in Breast Tumors Using a Permeability Model , 1995, Magnetic resonance in medicine.

[58]  J. Blasko,et al.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. , 2000, Seminars in urologic oncology.

[59]  P. Walsh.  Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. , 2005, The Journal of urology.

[60]  Greg Schaefer,et al.  Angiogenesis in Prostate Cancer: Biology and Therapeutic Opportunities , 2004, Cancer and Metastasis Reviews.

[61]  J. Kurhanewicz,et al.  Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. , 2004, Radiology.

[62]  F. Schick,et al.  Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla , 2006, Investigative radiology.

[63]  Thomas Hambrock,et al.  Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility , 2008, Investigative Radiology.

[64]  A. Jackson,et al.  Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI , 2006, Magnetic resonance in medicine.

[65]  J. Heverhagen,et al.  Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. , 2006, Magnetic resonance imaging.

[66]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[67]  J. L. Stephenson,et al.  Theory of the measurement of blood flow by the dilution of an indicator. , 1948, The Bulletin of mathematical biophysics.

[68]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[69]  Henkjan J Huisman,et al.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[70]  Adam S. Kibel,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .

[71]  Caroline Reinhold,et al.  Artifacts and pitfalls in MR imaging of the pelvis , 2007, Journal of magnetic resonance imaging : JMRI.

[72]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[73]  P. Asbach,et al.  Pharmakokinetische MRT der Prostata: Parameter zur Unterscheidung von Low-grade- und High-grade-Prostatakarzinomen , 2009 .

[74]  P. Choyke,et al.  Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies , 2008, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

[75]  Y. Ville,et al.  Placental perfusion and permeability: simultaneous assessment with dual-echo contrast-enhanced MR imaging in mice. , 2006, Radiology.

[76]  Thorsten Schlomm,et al.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study , 2010, World Journal of Urology.

[77]  John E Tomaszewski,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[78]  Tristan Barrett,et al.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. , 2007, AJR. American journal of roentgenology.

[79]  N. Rofsky,et al.  Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement , 2006, European Radiology.

[80]  J. Heitman,et al.  Microbial genetics: Love the one you're with , 2009, Nature.

[81]  J. Pouliot,et al.  Efficacy of external beam radiotherapy compared to permanent prostate implant in treating low risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and PSA , 2004 .

[82]  Wolfhard Semmler,et al.  Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI , 2004, European Radiology.

[83]  J. Concato,et al.  Molecular markers and mortality in prostate cancer , 2007, BJU international.

[84]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[85]  D. Buckley,et al.  Precision in measurements of perfusion and microvascular permeability with T1‐weighted dynamic contrast‐enhanced MRI , 2006, Magnetic resonance in medicine.

[86]  J. Battermann,et al.  Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. , 2010, International journal of radiation oncology, biology, physics.

[87]  P. Gabriele,et al.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging , 2009, European Radiology.

[88]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[89]  A. Partin,et al.  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate , 1997, Cancer.

[90]  Liang Cheng,et al.  Prostate needle biopsies , 2004, Cancer.

[91]  Evis Sala,et al.  Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. , 2006, Radiology.

[92]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[93]  J. Chapelon,et al.  Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI , 2009, European Radiology.

[94]  Stuart J. Russell,et al.  Do the right thing , 1991 .

[95]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[96]  William J Catalona,et al.  Serial biopsy results in prostate cancer screening study. , 2002, The Journal of urology.

[97]  D. Beyersdorff,et al.  Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. , 2005, Magnetic resonance imaging.

[98]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[99]  H. Hricak,et al.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. , 2008, Radiology.

[100]  D. Beyersdorff,et al.  MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. , 2005, AJR. American journal of roentgenology.

[101]  H. Sandler,et al.  A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.

[102]  A. Hanlon,et al.  Patterns and fate of PSA bouncing following 3D-CRT. , 2001, International journal of radiation oncology, biology, physics.

[103]  M. Brawer,et al.  Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.

[104]  Martin O Leach,et al.  Reference tissue quantification of DCE-MRI data without a contrast agent calibration , 2007, Physics in medicine and biology.

[105]  Olivier Rouvière,et al.  Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings. , 2004, Urology.

[106]  J. Heiken,et al.  Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. , 1993, Radiology.